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Abstract
Background: Combined small cell lung carcinoma (SCLC) is defined as SCLC combined with elements of non-small
cell lung carcinoma (NSCLC), accounting for approximately 30% of cases of SCLC. However, combined SCLC and
giant cell carcinoma (GC) is very rare.
Case presentation: A 50-year-old woman with a 45 pack-year smoking history was referred to our hospital for further
investigation of an abnormal left hilar shadow. Chest computed tomography (CT) revealed a 28-mm solid pulmonary
nodule in the left lower lobe and an enlarged left hilar lymph node adjacent to the left main pulmonary artery. CT-
guided biopsy of the pulmonary nodule led to the diagnosis of high-grade neuroendocrine carcinoma. The preoperative
clinical stage was defined as cT1bN1M0. Thus, the patient underwent left lower lobectomy with ND2a-2 lymph node
dissection via thoracotomy. Pathological investigation revealed a 22-mm tumor and dense sheet-like growth of small
tumor cells with scant cytoplasm and finely granular nuclear chromatin. Moreover, there was a sheet-like growth of
bizarre, highly pleomorphic mono- or occasionally multinucleated giant cells, accounting for approximately 40% of the
tumor. Both the small and giant cell components were thyroid transcription factor-1-positive and p40-negative and
exhibited neuroendocrine differentiation, as indicated by positivity for synaptophysin and CD56 and negativity for
chromogranin A. While the small cell component was E-cadherin-positive and vimentin-negative, the giant cell
component was E-cadherin-negative and vimentin-positive, indicating an epithelial-to-mesenchymal transition. Only the
small cell component was found within the mediastinal and hilar lymph nodes. The final pathological diagnosis was
combined SCLC and GC, pT1bN2M0, and pStage IIIA. The patient received adjuvant chemotherapy with 4 cycles of
cisplatin and irinotecan. No sign of recurrence has been noted for 1 year after the surgery.
Conclusions: This is the first detailed report of a unique case with combined SCLC and GC. The coexistence of SCLC and
GC in the presented case might indicate several possibilities: (1) GC may arise from SCLC via epithelial-to-mesenchymal
transition, (2) SCLC may arise from GC through phenotypic conversion, and (3) SCLC and GC may have derived from a
common neuroendocrine origin. Further investigation is necessary to reveal the underlying pathological process.
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Background
Combined small cell lung carcinoma (SCLC) is defined
as SCLC combined with elements of non-small cell lung
carcinoma, and it accounts for approximately 30% of
cases of SCLC [1]. However, SCLC combined with giant
cell carcinoma (GC) is very rare. Nicholson et al. have
reported the largest surgical case series of combined
SCLC, showing that NSCLC components were found in
28 of 100 SCLCs: 16 with large cell carcinoma, 9 with
adenocarcinoma, 3 with squamous cell carcinoma, but
none with GC [2]. Fishback et al. found that only 1 of 48
cases of GC, which accounts for approximately 0.3% of
all invasive lung malignancies, showed combined
pathology with SCLC [3], for which detailed clinical,
radiological, and pathological information were not
reported. We report a case of combined SCLC and GC
with preoperative medical images and findings of immu-
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Case presentation
A 50-year-old woman with a 45 pack-year smoking his-
tory was referred to our hospital for further investigation
of an abnormal left hilar shadow (Fig. 1a). The patient’s
medical history included hypertension, and the patient
had previously undergone an appendectomy at the age
of 35 years and an abdominal myomectomy at the age of
49 years. The levels of tumor markers were as follows:
carcinoembryonic antigen, 2.8 ng/mL; cytokeratin 19
fragment, 1.4 ng/mL; neuron-specific enolase, 21.0 ng/
mL; and pro-gastrin-releasing peptide, 84.4 pg/mL.
Chest contrast-enhanced computed tomography (CT)
revealed a 28-mm solid pulmonary nodule in the left
lower lobe (S6) and an enlarged left hilar lymph node
adjacent to the left main pulmonary artery (Fig. 1b, c).
18F-fluorodeoxyglucose (FDG) positron-emission tom-
ography/CT showed increased FDG uptake in the S6
nodule and the hilar lymph node, in which the max-
imum standard uptake values were 5.3 and 5.0, respect-
ively (Fig. 1d). CT-guided biopsy of the S6 nodule led to
the pathological diagnosis of high-grade neuroendocrine
carcinoma. Brain contrast-enhanced magnetic resonance
imaging showed no signs of brain metastasis. Thus, the
preoperative clinical stage was defined as cT1bN1M0.
The patient underwent left lower lobectomy with ND2a-
2 lymph node dissection via thoracotomy.
Pathological investigation revealed a 22 × 18 × 12-mm
nodule (Fig. 2a). Within the tumor, there was a dense
sheet-like growth of small tumor cells with scant cyto-
plasm and finely granular nuclear chromatin (Fig. 2b–d).
Moreover, there was a sheet-like growth of bizarre, highly
pleomorphic mono- or occasionally multinucleated giant
cells, accounting for approximately 40% of the tumor
(Fig. 2c, e). Both the small and giant cell components were
thyroid transcription factor 1 (TTF-1)-positive and p40-
negative, exhibiting neuroendocrine differentiation, as in-
dicated by positivity for synaptophysin and CD56 and
negativity for chromogranin A (Fig. 3a–c). While the small
cell component was E-cadherin-positive and vimentin-
negative, the giant cell component was E-cadherin-
negative and vimentin-positive, indicating epithelial-to-
mesenchymal transition (EMT) (Fig. 3d, e). Only the small
cell component was found within the mediastinal and
hilar lymph nodes. The final pathological diagnosis was
combined SCLC and GC, pT1bN2M0, pStage IIIA. The
patient received adjuvant chemotherapy with 4 cycles of
cisplatin and irinotecan. No sign of recurrence has been
noted for 1 year after the surgery.
Discussion
This is the first detailed report of a unique surgical case
with combined SCLC and GC. The coexistence of SCLC
and GC, epithelial and mesenchymal components, in the
presented case might indicate several possibilities that
should be investigated in further studies.
GC may arise from SCLC via EMT as SCLC pro-
gresses. Kuo et al. showed that normal pulmonary neu-
roendocrine cells are capable of EMT, sometimes called
“slithering” during their migration [4]. The slithering
program may contribute to EMT in SCLC, but the exact
mechanism remains unclear. Reportedly, SCLC may be
subdivided into two distinct classes based on its global
gene expression pattern: “neuroendocrine” class and
“mesenchymal-like” class, both of which can coexist [5].
The “mesenchymal-like” class SCLC might have the cap-
acity of converting into GC, but this speculation should
be further investigated.
Begin et al. found 4 autopsy cases of advanced SCLC
combined with GC among 409 biopsy or autopsy cases
during their 2-year study period [6]. They suggested that
SCLC might develop into GC regardless of irradiation,
because 3 of the 4 cases showed combined SCLC and GC
in the non-irradiated metastatic lesions. Furthermore,
Yamamoto and colleagues reported a rare case of esopha-
geal GC combined with small cell carcinoma, suggesting
the origin of GC may be associated with small cell carcin-
oma [7]. SCLC may arise from GC through phenotypic
conversion. Approximately 15% of patients with lung
Fig. 1 Medical imaging findings and gross appearance of the pulmonary nodule. a An abnormal left hilar shadow was observed (white arrow). b,
c Contrast-enhanced computed tomography of the chest revealed a solid 28-mm pulmonary nodule at S6 of the left lower lobe (white arrow). c
Hilar lymphadenopathy adjacent to the pulmonary artery was also found (asterisk). d FDG uptake was demonstrated in both the S6 nodule and
the hilar lymph node
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adenocarcinoma undergoing epidermal growth factor re-
ceptor tyrosine kinase inhibitor treatment experience
adenocarcinoma-to-SCLC conversion [8]. However, it is un-
clear whether GC-to-SCLC conversion can occur spontan-
eously with no treatment stimuli.
SCLC and GC may also be simultaneously derived
from monoclonal or multiclonal cells of origin. Report-
edly, SCLC develops from neuroendocrine precursors or
alveolar type 2 cells [5], whereas GC develops from
undifferentiated multipotent stem cells. However, it is
still unknown whether these precursors can differentiate
into two distinct tumor cell groups: SCLC and GC.
Further investigation is necessary to reveal the under-
lying pathological process.
Our patient was treated with 4 cycles of cisplatin and
irinotecan as postoperative chemotherapy. Accumulating
evidence supports the idea that patients with completely
resected pN2 SCLC or pN2 GC may benefit from
adjuvant chemotherapy [9–12]. However, since there are
only a few single-arm phase II studies evaluating
adjuvant chemotherapy for SCLC and no prospective
study investigating adjuvant chemotherapy for GC has
Fig. 2 Macroscopic and microscopic findings of the pulmonary nodule. a, b A 22 × 18 × 12-mm nodule was found in the left lower lobe of the
lung. c, d Pathological investigation revealed a dense sheet-like growth of small tumor cells with scant cytoplasm and finely granular nuclear
chromatin. e There was also a sheet-like growth of bizarre, highly pleomorphic mono- or occasionally multinucleated giant cells. HE, hematoxylin
and eosin, G giant cell component, S small cell component
Fig. 3 Immunohistochemical staining of the tumor. a Representative image of the tumor comprised of small cell component and giant cell
component (hematoxylin and eosin stain). b Both the small cell and giant cell components were TTF-1-positive and p40-negative. c Both the
small cell and giant cell components exhibited neuroendocrine differentiation (positive for synaptophysin and CD56 but negative for chromogranin
A). d, e While the small cell component was E-cadherin-positive and vimentin-negative, the giant cell component was E-cadherin-negative and
vimentin-positive, indicating EMT. HE hematoxylin and eosin, G giant cell component, S small cell component
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been reported to date, the optimal regimen for pN2 com-
bined SCLC and GC is unknown. Tsuchiya et al. reported
from their phase II study of 62 patients that complete re-
section of pStage I to IIIA SCLC followed by adjuvant
chemotherapy comprised of cisplatin and etoposide (PE)
showed favorable outcomes [9]. Specifically, they reported
a 5-year survival rate of 39% for pN2 SCLC. National
Comprehensive Cancer Network guidelines recommend
postoperative concurrent chemoradiotherapy for node-
positive SCLC, but it is not routinely performed in Japan
because local therapy is considered complete after surgery
and also because a meta-analysis by Warde et al. showed
that the addition of thoracic radiation therapy was associ-
ated with a 1.2% increased risk of treatment-related death
[13]. Cisplatin and irinotecan (PI) is associated with better
survival outcomes and less hematologic toxicity compared
to the PE regimen in SCLC patients younger than 70 years
who have extensive disease [14]. Additionally, PI has been
shown to be effective for advanced non-small cell lung
cancer [15, 16]. Based on these data along with the fact
that the GC component could be a phenotype of NSCLC,
a PI regimen was expected to be effective for both SCLC
and GC components in the presented case.
Conclusions
In conclusion, this is the first detailed report of a unique
surgical case with combined SCLC and GC. The coexist-
ence of SCLC and GC in the presented case might indi-
cate several possibilities: (1) GC may arise from SCLC
via epithelial-to-mesenchymal transition, (2) SCLC may
arise from GC through phenotypic conversion, and (3)
SCLC and GC may have derived from a common neuro-
endocrine origin. Further investigation is necessary to
reveal the underlying pathological process and to estab-
lish the optimal treatment strategy.
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